Loading quotes...

Forecast

The analysts' average price target is €2.72 (+28,145.07%). The median is €2.72 (+28,145.07%).

Buy
  2
Hold
  1
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Inotiv files for Chapter 11 and plans debt reduction

    Inotiv has filed a Chapter 11 petition with the US Bankruptcy Court for the Southern District of Texas and agreed to a pre‑negotiated restructuring plan with senior secured creditors and an ad hoc group of noteholders. The aim is to reduce liabilities of about $488 million by roughly $326 million; the company secured $25 million of DIP financing in addition to a previously provided $40 million bridge loan (a total of $65 million). Inotiv intends to continue operations, pay suppliers and wages in the ordinary course, and expects an expedited conclusion of the Chapter 11 proceedings. » More on de.investing.com


  • Inotiv: lenders suspend minimum liquidity requirement for April

    Inotiv’s lenders have agreed to waive the minimum liquidity covenant for the test dates on 3 and 10 April 2026. The exemption applies only to the minimum liquidity clause; other loan terms remain unchanged. Inotiv is under significant financial strain with $476m in total debt, a market capitalization of $8.92m and a current ratio of 0.3. The company also missed its Q1 2026 results and reported a cybersecurity incident discovered in August 2025 that may have compromised personal data. » More on de.investing.com


  • Cyberattack at Inotiv compromises sensitive employee data

    Inotiv reported a cyberattack in which unauthorized access to systems occurred between August 5 and August 8, 2025, and potentially exposed names, Social Security numbers, driver’s license numbers, financial and medical information of current and former employees and their dependents. The incident was discovered on August 8 and reported to the SEC on August 18; the company has launched investigations, engaged external security experts and authorities, and notified affected individuals. Inotiv is offering credit monitoring, has seen no misuse so far but urges increased vigilance; the stock is trading near its 52-week low and 2026 is still expected to show a negative EPS of -$0.26. » More on de.investing.com


  • Inotiv receives preliminary court approval for $2.49 million derivatives settlement

    The U.S. District Court for the Northern District of Indiana granted Inotiv preliminary approval of a proposed settlement in two consolidated derivative suits, which provides for the implementation of certain corporate governance measures and a payment of $2.49 million. The payment is to be funded from insurance proceeds; attorneys’ fees of up to $2.25 million are also expected to be covered by insurance. A hearing for final approval is scheduled for March 18, 2026. » More on de.investing.com


  • Inotiv enters partnership with VUGENE to accelerate AI-driven drug discovery

    Inotiv announced a strategic collaboration with VUGENE to integrate VUGENE’s cloud-based multi-omics bioinformatics and AI platform into its Discovery & Translational Sciences division, aiming to improve analysis of complex biological data for drug discovery. The cooperation is intended to enhance early-stage predictions of efficacy and safety and to give VUGENE the opportunity to expand its technologies in research settings. Despite significant financial strain at Inotiv (sharp share decline, current ratio 0.35, debt-to-capital 0.94), the company beat Q4 2025 expectations with earnings of -$0.25 per share (expected -$0.33) and revenue of $138.1 million (expected $132.54 million). » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2001, Inotiv has already paid €0.0691 in dividends. The last payout was in June 2001.

Financials

In the last quarter, Inotiv had revenue of €101.64m and net profit of -€28.05m
(EUR) March 2026
YoY
Revenue 101.64m -
Gross profit 9.13m -
Net profit -28.05m -
EBITDA -1.98m -

Fundamentals

Metric Value
Market capitalization
€2.53m
Number of shares
34.89m
52-week high/low
€2.21 - €0.0151
Dividends No
Beta
4.08
P/E ratio
0.00
PEG ratio
0.00
P/B ratio
0.00
P/S ratio
0.00

Company profile

Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.

Name
Inotiv
CEO
Robert W. Leasure
Headquarters West Lafayette, in
USA
Website
Sector
Industrials
Industry
Aerospace & Defense
IPO
25/11/1997
Employees 2,027

Ticker symbols

Exchange Symbol
NASDAQ
NOTV
Frankfurt
BS50.F
Düsseldorf
BS50.DU
München
BS50.MU
🍪

Parqet  uses cookies. Learn more